{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:12:51Z","timestamp":1787339571668,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jcf.2020.11.002","type":"journal-article","created":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T01:08:09Z","timestamp":1607216889000},"page":"250-256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)"],"prefix":"10.1016","volume":"20","author":[{"given":"Shamsah","family":"Kazani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Rowlands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Bottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-2143","authenticated-orcid":false,"given":"Julie","family":"Milojevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Alcantara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ieuan","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kulmatycki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Machineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Mostovy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry A.","family":"Nick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Vegesna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2708-354X","authenticated-orcid":false,"given":"Jeroen","family":"Verheijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Danahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gosling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phaninatha Sarma","family":"Ayalavajjala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1516-2390","authenticated-orcid":false,"given":"Robert","family":"Strieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2020.11.002_bib0001","unstructured":"Annual Data Report 2017. Cystic Fibrosis Foundation Patient Registry. Available from: https:\/\/www.cff.org\/Research\/Researcher-Resources\/Patient-Registry\/2017-Patient-Registry-Annual-Data-Report.pdf. Accessed 17 October 2019."},{"issue":"1","key":"10.1016\/j.jcf.2020.11.002_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2796.2006.01744.x","article-title":"Evidence for airway surface dehydration as the initiating event in CF airway disease","volume":"261","author":"Boucher","year":"2007","journal-title":"J Intern Med"},{"issue":"9678","key":"10.1016\/j.jcf.2020.11.002_bib0003","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2020.11.002_bib0004","series-title":"The metabolic and molecular basis of inherited disease","first-page":"5121","article-title":"Cystic fibrosis","author":"Welsh MJ","year":"2001"},{"issue":"18","key":"10.1016\/j.jcf.2020.11.002_bib0005","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcf.2020.11.002_bib0006","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2020.11.002_bib0007","doi-asserted-by":"crossref","first-page":"i859","DOI":"10.1136\/bmj.i859","article-title":"New and emerging targeted therapies for cystic fibrosis","volume":"352","author":"Quon","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jcf.2020.11.002_bib0008","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jcf.2020.11.002_bib0009","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"Suppl 40","key":"10.1016\/j.jcf.2020.11.002_bib0010","first-page":"S3","article-title":"Breakthrough therapies: cystic fibrosis (CF) potentiators and correctors","volume":"50","author":"Solomon","year":"2015","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2020.11.002_bib0011","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1124\/mol.118.112177","article-title":"Lipophilicity of the cystic fibrosis drug, ivacaftor (VX-770), and its destabilizing effect on the major CF-causing mutation: F508del","volume":"94","author":"Chin","year":"2018","journal-title":"Mol Pharmacol"},{"issue":"S38","key":"10.1016\/j.jcf.2020.11.002_bib0012","first-page":"S231","article-title":"NVP-QBW251, a novel CFTR potentiator for the treatment of cystic fibrosis","volume":"49","author":"LeGrand","year":"2014","journal-title":"Pediatric Pulmonol"},{"key":"10.1016\/j.jcf.2020.11.002_bib0013","unstructured":"Novartis data on file."},{"issue":"2","key":"10.1016\/j.jcf.2020.11.002_bib0014","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2008.05.005","article-title":"Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report","volume":"153","author":"Farrell","year":"2008","journal-title":"J Pediatr"},{"issue":"7","key":"10.1016\/j.jcf.2020.11.002_bib0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.jcf.2020.11.002_bib0016","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2020.11.002_bib0017","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2016.10.009","article-title":"Biomarkers for cystic fibrosis drug development","volume":"15","author":"Muhlebach","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2020.11.002_bib0018","unstructured":"Vertex Pharmaceuticals Incorporated. KalydecoTM (ivacaftor) tablets and oral granules, for oral use: US prescribing information. 2012, revised July, 2017. Accessed July 2019."},{"issue":"21","key":"10.1016\/j.jcf.2020.11.002_bib0019","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcf.2020.11.002_bib0020","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jcf.2020.11.002_bib0021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2019.09.013","article-title":"Ivacaftor in cystic fibrosis with residual function: lung function results from an N-of-1 study","volume":"19","author":"Nick","year":"2020","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932030905X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932030905X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:43:43Z","timestamp":1761601423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932030905X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S156919932030905X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2020.11.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2020.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}